Great story in the AFR, quoting Paul Hopper stating biotech are heading for a new lease of life as China is on opening its door to for better patient access to western drugs and are in the mood for a buy up biotech companies. International bio investors are buying up life science companies in Australia that were unheard of a decade ago.
However and this is a laugh, one area that Australia needs to improve on is stricter rules on corporate governance as "ASX biotechs often exaggerate the significance of their data, even if Australian science can often be world-class,"
KZA Price at posting:
55.5¢ Sentiment: Buy Disclosure: Held
